Literature DB >> 35764811

Nationally Validated Scoring System to Predict Unplanned Reoperation and Readmission after Breast Reduction.

Theresa K Webster1, Pablo A Baltodano1, Xiaoning Lu2, Huaqing Zhao2, Nicholas Elmer3, Karen E Massada4, Juliet Panichella1, Rohan Brebion1, Sthefano Araya1, Sameer A Patel5,6.   

Abstract

BACKGROUND: Reduction mammoplasty continues to be a commonly sought procedure with complication rates ranging from 4.3 to 8.2%. In the current study, we sought to identify the clinical and preoperative risk factors for unplanned reoperation and readmission within the first postoperative month on a national scale.
METHODS: Patients who underwent reduction mammoplasty from the ACS-NSQIP 2012-2019 database were analyzed to determine rates of reoperation and readmission within 30 days of the initial breast surgery. The cohort was divided into 60 and 40% random testing and validation samples. A multivariable logistic regression analysis was then performed to isolate independent factors of unplanned readmission and reoperation using the testing sample (n = 22,743). The predictors were weighted according to beta coefficients to develop an integer-based clinical risk score predictive of complications. This system was then validated using receiver operating characteristics (ROC) analysis of the validation sample (n = 15,162).
RESULTS: A total of 37,905 reduction mammoplasties were analyzed. 1.3% of patients had an unplanned readmission. Independent risk factors for unplanned readmission included age older than the median of 44 years (p < 0.01), inpatient procedure (p < 0.01), smoking (p < 0.01), hypertension (p = 0.01), COPD (p < 0.05), BMI ≥ 35 (p < 0.01), and operation time greater than the median of 142 minutes ( p < 0.01). The factors were integrated into a scoring system, ranging from 0 to 36, and an ROC analysis revealed an area under the curve of 0.66. 1.9% of patients underwent unplanned reoperation. Independent risk factors for unplanned reoperation in this population included age older than the median of 44 years (p < 0.01), inpatient status (p < 0.01), and a history of bleeding disorders (p < 0.05). The factors were integrated into a scoring system, ranging from 0 to 25, and the ROC analysis revealed an area under the curve of 0.61.
CONCLUSIONS: We present a validated scoring system to better inform patients about their risk for unplanned reoperation and readmission following reduction mammoplasty. This system will enable surgeons to optimize patient selection and interventions in order to decrease morbidity and unnecessary health-care expenditure. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.

Entities:  

Year:  2022        PMID: 35764811     DOI: 10.1007/s00266-022-02966-9

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  18 in total

1.  Analysis of breast reduction complications derived from the BRAVO study.

Authors:  Bruce L Cunningham; Andrew J L Gear; Carolyn L Kerrigan; E Dale Collins
Journal:  Plast Reconstr Surg       Date:  2005-05       Impact factor: 4.730

2.  Standardizing the complication rate after breast reduction using the Clavien-Dindo classification.

Authors:  Raimund Winter; Isabella Haug; Patricia Lebo; Martin Grohmann; Frederike M J Reischies; Janos Cambiaso-Daniel; Alexandru Tuca; Theresa Rienmüller; Herwig Friedl; Stephan Spendel; Abigail A Forbes; Paul Wurzer; Lars-P Kamolz
Journal:  Surgery       Date:  2016-12-30       Impact factor: 3.982

3.  Risk factors for complications following breast reduction: results from a randomized control trial.

Authors:  Narasimhaiah Srinivasaiah; Obi C Iwuchukwu; Paul R W Stanley; Nicholas B Hart; Alastair J Platt; Philip J Drew
Journal:  Breast J       Date:  2014 May-Jun       Impact factor: 2.431

4.  Obesity and early complications following reduction mammaplasty: an analysis of 4545 patients from the 2005-2011 NSQIP datasets.

Authors:  Jonas A Nelson; John P Fischer; Cyndi U Chung; Ari West; Charles T Tuggle; Joseph M Serletti; Stephen J Kovach
Journal:  J Plast Surg Hand Surg       Date:  2014-02-10

Review 5.  Assessing Risk and Avoiding Complications in Breast Reduction.

Authors:  Kenneth C Shestak; Edward H Davidson
Journal:  Clin Plast Surg       Date:  2016-02-02       Impact factor: 2.017

6.  Complications following reduction mammaplasty: a review of 3538 cases from the 2005-2010 NSQIP data sets.

Authors:  John P Fischer; Emily C Cleveland; Eric K Shang; Jonas A Nelson; Joseph M Serletti
Journal:  Aesthet Surg J       Date:  2013-12-13       Impact factor: 4.283

7.  Early complications of a reduction mammoplasty technique in the treatment of macromastia with or without breast cancer.

Authors:  Mehmet Ali Gulcelik; Lutfi Dogan; Mithat Camlibel; Niyazi Karaman; Bekir Kuru; Haluk Alagol; Cihangir Ozaslan
Journal:  Clin Breast Cancer       Date:  2011-10-10       Impact factor: 3.225

8.  Risk factors and complications in reduction mammaplasty: novel associations and preoperative assessment.

Authors:  Steven L Henry; J Lauren Crawford; Charles L Puckett
Journal:  Plast Reconstr Surg       Date:  2009-10       Impact factor: 4.730

9.  A Comparative Retrospective Analysis of Complications After Oncoplastic Breast Reduction and Breast Reduction for Benign Macromastia: Are These Procedures Equally Safe?

Authors:  Thomas A Imahiyerobo; Lindsay A Pharmer; Alexander J Swistel; Mia Talmor
Journal:  Ann Plast Surg       Date:  2015-10       Impact factor: 1.539

Review 10.  Controllable Factors to Reduce the Rate of Complications in Primary Breast Augmentation: A Review of the Literature.

Authors:  Paolo Montemurro; Per Hedén; Björn Behr; Christoph Wallner
Journal:  Aesthetic Plast Surg       Date:  2020-05-01       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.